Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the effect of Dexamethasone on postoperative pain and nausea after hip arthroscopy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
Hip arthroscopy (HAS) is a standard procedure with good mid and long-term results. Postoperative pain is a great concern and postoperative pain management of great importance. High demand for opiates and the associated side effects especially nausea limit the postoperative rehabilitation.
Promising results to reduce postoperative pain and nausea have been achieved by perioperative dexamethasone, which has a strong anti-inflammatory effect reducing pain and inflammation as well as a strong anti-emetic effect, especially in total hip replacement.
It is our goal to compare the effect of perioperative intravenous dexamethasone (3x 4mg Amp. Fortecortin =12mg prior to surgery and 3x4mg Amp. Fortecortin = 12mg at 8.00am of the first postoperative day in 250ml saline solution) to a control group (placebo) (1x 250ml saline solution postoperative day 1 at 8.00am) regarding pain level, opiate consumption, postoperative nausea and patient satisfaction.
A double-blinded prospective randomized control trial including 60 patients receiving elective unilateral HAS will be conducted.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Dexamethasone group The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg dexamethasone intravenously (Fortecortin®) on the first postoperative day at approx. 8.00a.m. by the investigators. |
Drug: Dexamethasone 4mg
s. arm/group description
Other Names:
|
| Placebo Comparator: Placebo/ Control group The patients will not receive any additional drugs preoperatively. A 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators. |
Drug: NaCl 0.9%
s. arm/group description
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Postoperative pain level [6 hours postoperatively]
The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (wost possible pain).
- Postoperative pain level [24 hours postoperatively]
The VAS Pain score assesses pain Levels on a scale from 0 (no pain) to 10 (wost possible pain).
- Amount of opiates (morphinequivalent) consumed [48 hours postoperatively]
We will assess the amount of Opiates the Patient needed due to the performed Surgery during the hospital stay.
- Amount of anti-emetics consumed (Ondansetron) [48 houts postoperatively]
We will assess the amount of mg of anti- emetic drugs (Ondansetron) the Patient required during the Hospital stay.
Secondary Outcome Measures
- Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [6 hours postoperatively]
Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).
- Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [24 hours postoperatively]
Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).
- Patient satisfaction as assessed by the revised American pain society patient outcome questionnaire [48 hours postoperatively]
Patient satisfaction will be assessed by the revised American pain Society Patient Outcome questionnaire (APS-POQ-R).
- Number of vomiting events [48 hours postoperatively]
We will Count the number of vomiting Events postoperatively as a direct marker for postoperative Nausea.
- Physical therapy milestones [48 hours postoperatively]
Our patients will be instructed and perform different postoperative Rehabilitation steps including (first steps in the hallway, Walking up and down stairs, bicycle Ergometer)
- Length of hospitalization [after 1 week]
The length of hospitalization will be obtained from the Patient Chart.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• Age ≥ 18 years
-
general anasthesia
-
Elective isolated unilateral HAS for any reason
-
No Prior hip surgery
-
Written informed consent as documented by signature (Appendix Informed Consent Form)
-
Competent German language skills
Exclusion Criteria:
-
• Chronic pain patient, chronic lower back pain
-
Steroid or immunosuppressive drugs used within 6 months of surgery
-
Renal failure, hepatic failure
-
Relevant allergies
-
Pregnancy/ Breast feeding
-
Contraindications for Fortecortin treatment according to Swissmedic
-
Previous enrollment into the current study
-
Participation in another study with investigational drug within the 30 days preceding and during the present study
-
Known or suspected non-compliance, drug or alcohol abuse
-
Illness according to "Warnings and Precautions of Dexamethasone and NaCl"
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Uniklinik Balgrist | Zürich | Switzerland | 8008 |
Sponsors and Collaborators
- Balgrist University Hospital
Investigators
- Principal Investigator: Patrick Zingg, MD, PI
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DEXA and HAS